drugset / Trial / NCT07597395
ATRA for Management of Primary ITP
Phase 3
Not yet recruiting
192 enrolled
Peking University People's Hospital
Beijing Friendship Hospital · collabBeijing Hospital · collabBeijing Tongren Hospital · collabPeking University First Hospital · collabPeking University Third Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multicenter, randomized, double-blind placebo-controlled study to report the efficacy and safety of all-trans etinoic acid compared to placebo for the treatment of adults with corticosteriod-resistant/relapsed primary immune thrombocytopenia (ITP).
Timeline
- Start
- 2026-05-30
- Primary completion
- 2027-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tretinoin | Small molecule | 10 mg | — |